WHO ICTRP trial
CAR-T cell therapy by targeting at BCMA/CS1/CD19 in patients with…
ChiCTR2000033131 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2000033131 |
|---|---|
| Public title | CAR-T cell therapy by targeting at BCMA/CS1/CD19 in patients with relapsed/refractory malignant plasmacyte disease |
| Scientific title | The safety and efficacy of CAR-T cell therapy by targeting at BCMA/CS1/CD19 in patients with relapsed/refractory malignant plasmacyte disease: an open labeled and single center study |
| Primary sponsor | Department of Hematology, The First Affiliated Hospital of Xiamen University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 0 |
| Countries | China |
| Conditions | Relapsed/refractory Malignant plasmacyte disease |
| Interventions | ICG186-1 low dose:BCMA-CAR-T cells (ICG186)2.5 x10*5/kg;ICG186 low- intermediate dose:BCMA-CAR-T cells (ICG186)5 x10*5/kg;ICG186 intermediate-high dose:BCMA-CAR-T cell (ICG186)10 x10*5/kg;ICG186 high dose:BCMA-CAR-T cells (ICG186)20… |
| Registration date | May 21, 2020 |
| Target size | ICG186-1 low dose:3;ICG186 low- intermediate dose:3;ICG186 intermediate-high… |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: